Boehringer Ingelheim has joined forces with digital health firm Brainomix on a project to improve the care of people with fibrosing lung diseases in the US.
Two experimental therapies from Vicore Pharma and Endeavor BioMedicines that could provide new ways of treating idiopathic pulmonary fibrosis (IPF) have shown encouraging
Artificial intelligence company Brainomix has claimed FDA approval for e-Lung, which assists in the diagnosis and assessment of patients with interstitial lung diseases (ILDs) from me
Endeavor BioMedicines has completed a third round financing, raising an impressive $132.5 million to fund trials of its two clinical-stage drug candidates for pulmonary fi
Artificial intelligence-powered software developed by Brainomix has been shown to identify patients with idiopathic pulmonary fibrosis (IPF) at risk of decline in a clinic
Swedish pharma company Vicore has won breakthrough status from the FDA for Almee, a cognitive behavioural therapy (CBT) app used to support people with pulmonary fibrosis
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh